Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Avidity Biosciences (RNA – Research Report). The associated price target remains the same with $50.00. Yanan Zhu has given his Buy ...
Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
12 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:RNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...
Avidity BiosciencesRNA saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 80 to 93. Please watch the video at Investors.com - What Are The Magnificent Seven ...
SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ...
Novartis AG will acquire Avidity Biosciences, Inc. for $12bn, aiming to strengthen its neuroscience franchise and xRNA strategy with late-stage muscle disease assets. The deal brings three late-stage ...
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...
Targeting rare cardiomyopathy conditions with no approved disease-modifying therapies, Atrium Therapeutics Inc. started operations in San Diego, assuming the public listing and technology once held by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results